Psychiatry

News

Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.

R&D

pharmaphorum speaks with Hans Eriksson, psychiatrist and CMO of FundaMental Pharma, about why treatment resistance remains such a challenge.

News

The list of illnesses that may benefit from treatment with GLP-1 drugs gets ever longer, and a study has found that schizophrenia may be an addition.

Patients

After a schizophrenia diagnosis, families must learn how to navigate treatment, respond to symptoms, and communicate effectively.

Digital

The state of the public’s mental health in the UK and Europe is a serious unmet need.

Patients

Mental disorders account for a significant share of economic cost across EU Member States and the United Kingdom.